Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study

发表于 2026-9-28 16:19:52

期刊：Annals of Oncology

文献作者：J. Zhang; Y. Meng; Y. Du; T. Sun; J. Cui; Y. Chen; Y. Sun; Y. Wang; W. Chen; F. Xu; Y. Shi; Y. Chen; K. Wang; G. Jin; H. Zhou; Z. Zhuang; W. Xie; Z. Wang; M. Sun; Q. Wen; X. Wang; C. Wang; S. Xiao; H. Zhu; Y. Zhu; J. Wu

出版日期：2026-9-

DOI号：10.1016/j.annonc.2026.09.002

下载链接：https://www.sciencedirect.com/sc ... 923753426066342/pdf

文献链接：https://doi.org/10.1016/j.annonc.2026.09.002

当前文献来源于 Elsevier BV。

备注信息：

发表于 2026-9-28 16:19:53

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[Elsevier/Sciencedirect] Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Elsevier/Sciencedirect] Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study 一键复制